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ABSTRACT 
Objective: The objective of this study was to 
determine the changes in cognitive function of 
anthracycline-based adjuvant chemotherapy in 
women with breast carcinoma. 
Method: The study design was prospective 
longitudinal study. The breast cancer patients who 
rece ived  an thracyc l ine -based  ad juvan t  
chemotherapy were recruited from Internal 
Medicine Department wards and TULIP cancer 
outpatient clinic Sardjito General Hospital 
Yogyakarta. Subjects eligible with inclusion and 
exclusion criteria were examined for cognitive 
function by mini-mental state examination (MMSE) 
nd before chemotherapy (T ) at 3 weeks after 20
th adjuvant chemotherapy (T ), 3 weeks after 41
th adjuvant chemotherapy (T ), and 3 months after 42
adjuvant chemotherapy (T ). The mean difference of 3
MMSE scores were analyzed with Wilcoxon-signed 
rank test and P<0.05 was considered statistically 
significant. 
Result. There were 47 subjects eligible to 
st st study criteria in October 1 2008 – October 31
2009. Forty subjects finished this study and were 
analyzed. The mean age was 47.08±6.65 with age 
ranged from 27 to 61 years old. The mean MMSE 
nd scores before chemotherapy (T ), 3 weeks after 20
th adjuvant chemotherapy (T ), 3 weeks after 41
th adjuvant chemotherapy (T ), and 3 months after 42
adjuvant chemotherapy (T ) were 29.28±1.20, 3
28.60±1.69, 28.18±1.89, and 27.85±2.03, 
respectively. The mean MMSE score changes (ÄT -0
T ), (ÄT -T ), and (ÄT -T ) were 0.68±0.80, 1 0 2 0 3
1.10±1.06, and 1.43±1.36, respectively and 
P<0.001. The incidence of cognitive impairment 
with MMSE scores < 24 was 2.5% and P=1.0. 
Conclusion: There was a significant 
decline of MMSE score in women with breast 
carcinoma who received anthracycline-based 
nd adjuvant chemotherapy at 3 weeks after 2 adjuvant 
t h  chemotherapy, 3 weeks after 4 adjuvant 
th chemotherapy, and 3 months after 4 adjuvant 
chemotherapy  compared  wi th  pr ior  to  
chemotherapy. 
Key Words: Cognitive Function, Breast Cancer, 
Adjuvant Chemotherapy, Anthracycline
INTRODUCTION 
Breast Cancer is the most common cancer in 
women. In US, 20-24 years old women had lowest 
incidence of breast cancer. In 2000-2004, 1.4 cases 
per 100.000 women, and 75-79 years old women had 
the highest incidence reaching 464.8 cases per 
1100.000 women . Cancer incidence in Indonesia has 
not well known yet due to unavailable registration 
data. Data from Globocan, an International Agency 
for Research on Cancer (IARC) in 2002, and 
estimated breast cancer incidence in Indonesia is 26 
per 100.000 women. Breast cancer is the second 
most leading cancer in Indonesia after cervical 
cancer on pathological-based study, with relative 
2frequency 15.83% after cervical cancer 25.7% .
Data from TULIP Integrated Cancer Clinic 
Sardjito General Hospital Yogyakarta said that from 
one year to another, there was an increase in breast 
cancer cases. In 2005, from 1269 women visiting 
TULIP, the most case was breast cancer (31.1%) 
followed by cervical cancer (4.9%) and the most 
cases were 46 – 50 years old. One study in 
Yogyakarta showed a transformed trend of age of 
patient to the younger patient than in western 
countries accompanied with aggressive phenotypic. 
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Table 1. Baseline Characteristics of the Study Subject
Subject Variable
 (n=40)
 
Mean±SD
 
Median
 (minimum-maximum)
 Age (year)
 
47.08±6.65
 
48 (27 –
 
61)
 Educational Level(%)
   -
 
Elementary School
 
19 (47.5)
  -
 
Junior High School
 
6 (15.0)
  -
 
Senior High School
 
8 (20.0)
  -
 
Undergraduate
 
7 (17.5)
  Body Weight (Kg)
 
56.63±9.63
 
56.5 (36.0 –
 
75.0)
 Height (m)
 
153.35±4.79
 
154 (142 –
 
162)
 BMI (kg/m2)
 
24.05±3.74
 
23.9 (15.79 –
 
33.78)
 Menopausal state (%)
   -
 
Menstrual
 
23 (57.5)
  -
 
Menopause
 
17 (42.5)
  Stage (%)
   -
 
IIA
 
13 (32.5)
  -
 
IIB
 
9 (22.5)
  -
 
IIIA
 
9 (22.5)
  -
 
IIIB
 
9 (22.5)
  Chemotherapy regiment (%)
   -
 
AC
 
35 (87.5)
  -
 
EC
 
5 (12.5)
  Histopatology (%)
   -
 
Ductal Carcinoma
 
38 (95.0)
  -
 
Papillary
 
Carcinoma
 
2
 
(5.0)
  Comorbid (%)
   -
 
None
 
34 (85.0)
  -
 
Hypertension
 
4 (10.0)
  -
 
Diabetic
 
2 ( 5.0)
  MMSE score
 
29.28±1.20
 
30 (26 –
 
30)
 BMI = Body Mass Index, AC = adriamycin + cyclophosphamide, EC = Epirubicin + cyclophosphamide, MMSE = Mini Mental State 
Examination, SD = Standard Deviation
data was used to measure mean differences between 
first and second, third and fourth measurement, 
because data was not normally distributed. Multiple 
linear regressions were used to measure effect of 
anthracycline based adjuvant chemotherapy to 
cognitive function change with controlling other 
independent variables. Statistic evaluation was done 
with computer software. Statistical significant 
differences was considered if P<0.05.
RESULT AND DISCUSSION
st stFrom October 1  2008 to October 31  2009, 
there were 47 subjects fulfilled inclusion criteria. 
There were 7 dropped-out subjects due to 
incomplete chemotherapy. In total, there were 40 
subjects finishing the study and analyzed. Subject 
age mean was 47.08±6.65 with median 8 years old 
and interval 27-61 years old (table1). This was in 
accordance with epidemiological data from study in 
Yogyakarta which showed the age of most breast 
2.cancer patients at 40-49 years old
In this study, we observed cognitive 
function with MMSE of more homogenous sample 
population, relatively same type of chemotherapy 
and longer time of observation (interval 180 days 
from baseline). Iconomou et al. (2004) studied 
cognitive function using MMSE before and after 
chemotherapy on 80 solid tumor patients including 
breast cancer patients undergone chemotherapy. He 
found MMSE score mean before chemotherapy was 
26.89±3.05 (p=0.26), MMSE score <24 was 15% 
before chemotherapy and 15% after chemotherapy 
9(p=1.0) .
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ndTable 2. MMSE score mean difference 3 weeks after 2  adjuvant chemotherapy
Measurement T0
(Mean±SD) T1(Mean±SD)  ? T0- T1(Mean±SD)  P value
Orientation
 
9.88±0.34
 
9.83±0.45
 
0.05±0.22
 
0.157*
 
Registration
 
3.00±0.00
 
3.00±0.00
 
0.00±0.00
 
1.0*
 
Attention&Calculation
 
4.83±0.39
 
4.63±0.71
 
0.20±0.46
 
0.011*
 
Memory
 
2.93±0.27
 
2.68±0.47
 
0.25±0.49
 
0.004*
 
Language
 
8.68±0.62
 
8.48±0.75
 
0.20±0.41
 
0.005*
 
MMSE Score
 
29.28±1.20
 
28.60±1.69
 
0.68±0.80
 
<0.001*
 
ndT = before chemotherapy, T  = 3 weeks after 2  adjuvant chemotherapy, SD = Standard Deviation, MMSE = Mini Mental 0 1
State Examination, * Wilcoxon-signed rank test
thTable 3.  MMSE score mean difference 3 weeks after 4  adjuvant chemotherapy
Measurement T0 
(Mean±SD) T1  (Mean±SD)  ?  T0-  T1  (Mean±SD)  P  value  
Orientation 9.88±0.34 0  9.65±0.7  0.23±0.53  0.014*  
Registration 3.00±0.00  3.00±0.00  0.00±0.00  1.0*  
Attention&Calculation 4.83±0.39  4.43±0.78  0.40±0.55  <0.001*  
Memory 2.93±0.27  2.68±0.53  0.25±0.49  0.004*  
Language 8.68±0.62  8.43±0.75  0.25±0.59  0.012*  MMSE Score
 
29.28±1.20 
 
28.18±1.89
 
1.10±1.06
 
<0.001*
 
T = before chemotherapy, T  = 3 weeks after IV adjuvant chemotherapy, SD = Standard Deviation, MMSE = Mini Mental 0 1
State Examination, * Wilcoxon-signed rank test
thTable 4. MMSE score mean difference 3 months after 4  adjuvant chemotherapy
Measurement
 
T0
 (Mean±SD)
 
T1
 (Mean±SD)
 
?
 
T0-
 
T1
 (Mean±SD)
 
P
 
value
 
Orientation
 
9.88±0.34 
 
9.63±0.63
 
0.25±0.49
 
0.004*
 Registration
 
3.00±0.00 
 
3.00±0,00
 
0.00±0.00
 
1.0*
 
Attention&Calculation
 
4.83±0.39 
 
4.38±0.87
 
0.45±0.68
 
0.001*
 
Memory
 
2.93±0.27 
 
2.58±0.59
 
0.35±0.58
 
0.001*
 
Language 8.68±0.62 8.28±0.85 0.40±0.67 0.001*
MMSE Score 29.28±1.20 27.85±2.03 1.43±1.36 <0.001*
thT = before chemotherapy, T  = 3 months after 4  adjuvant chemotherapy, SD = Standard Deviation, MMSE = Mini 0 1
Mental State Examination, * Wilcoxon-signed rank test
On table 2, 3 and 4 there were MMSE score decrease 
ndon week 3 after 2  adjuvant chemotherapy, 3 weeks 
thafter 4  adjuvant chemotherapy and 3 months after 
th4  adjuvant chemotherapy compared with prior to 
anthracycline based adjuvant chemotherapy. These 
decreases were statistically significant (p<0.001). 
From five MMSE sub scores, there were some 
statistically significant decreases (p<0.05) on 
attention and calculation, memory, and language 
functions in compare with prior to chemotherapy, 
while orientation function only decreased 
significantly on 3 weeks (p=0.014) and 3 months 
th(p=0.004) after 4   adjuvant chemotherapy.
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Table 8. Linear Regression between MMSE score change (? T T ) 0- 3
and educational state and stage of cancer
Variable B SE â t P value  95% IC
Constanta 1.909 0.700  2.727 0.010  0.491–  3.328
Education -0.617 0.153 -0.539 -4.044 <0.001  -0.926 -  -0.308
Stage 0.549 0.359 0.204 1.529 0.135  -0.178 – 1.276
There were some limitations in this study. 
First, depression and anxiety were not measured in 
this study because the author did not have objective 
parameters to measure depression and anxiety. 
Second, this study design was a pre-post- analysis 
study without control group, so effect of exposure to 
outcome could not certainly be defined. Third, 
patients did not visit as scheduled and limited time 
of observation. 
CONCLUSION
In this study, there was a significant 
decrease on MMSE score of breast cancer patient 
thT = before chemotherapy, T  = 3 months after 4  adjuvant chemotherapy, B = â estimation, SE = Standard Error, CI = 0 3
Confidence Interval, MMSE = Mini Mental State Examination
19attention, learning, and memory . In this study, 
there was no significant mean MMSE score change 
based on age or menopausal status (table 7).
In this study (table 7), there was a 
significant MMSE score mean decrease on stage II 
in compare with stage III breast cancer patients. 
This might happen due to disease progressivity as 
indirect factor, beside anti-neoplastic therapy which 
had contribution on cancer patient cognitive 
19,20deficit .
Anemia was a common side effect of cancer 
and/or chemotherapy which could cause fatigue and 
brain oxygenation decrease. Jacobsen reported that 
patient with worse anemia level showed worse 
memory visual image and executive function than 
patient with normal hemoglobin or mild anemia. 
This effect had relationship with fatigue. This 
mechanism could cause acute cognitive impairment 
but less possible causing cognitive impairment 
7when hemoglobin level improved to normal . In this 
study anemia did not significantly influence 
decrease of MMSE score (table 7). This may be 
because the anemia was a mild anemia (hemoglobin 
level 9.0-11.0g/dl).
Beside that, side effect during other 
chemotherapy also did not significantly influence 
MMSE score decrease (table 7). This may be due to 
no incidence of febrile neutropenia during or after 
chemotherapy. Febrile and infection were also 
indirect factors which had contribution on cancer 
patient cognitive impairment beside antineoplastic 
19,20therapy .
Table 8 showed that on multivariate 
analysis, educational level had the greatest 
influence on MMSE score decrease, with p < 0.001 
(95% CI: -0.926- -0.308). It means that breast 
cancer patients receiving anthracycline based 
adjuvant chemotherapy with lower educational 
level has more significant MMSE score decrease 
than breast caner patient with higher educational 
state. This study was in line with study which said 
that education could give more protection on neuron 
degradation or delayed dementia onset. Education 
could improvise neuron to do the functional task of 
other dying neuron. Brain will degenerate faster 
when rarely used. Education could also increase 
brain memory by increasing neuro-cortical synaps 
21density .
receiving anthracycline based adjuvant  
ndchemotherapy on 3 weeks after 2  adjuvant 
thchemotherapy, 3 weeks after 4  adjuvant 
thchemotherapy and after 3 months after 4  adjuvant 
chemotherapy in compare with prior to 
chemotherapy.
SUGGESTION
Cognitive function evaluation of breast 
cancer patients receiving adjuvant chemotherapy is 
needed. It is needed especially for chemotherapy 
that contains neurotoxicity agent, to improve 
patients' quality of life.
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